Atea Pharmaceuticals Gestione
Criteri Gestione verificati 4/4
Atea Pharmaceuticals Il CEO è Jean-Pierre Sommadossi, nominato in Jul2012, e ha un mandato di 13.83 anni. la retribuzione annua totale è $ 3.40M, composta da 20.7% di stipendio e 79.3% di bonus, comprese azioni e opzioni aziendali. possiede direttamente 8.29% delle azioni della società, per un valore di $ 30.05M. La durata media del mandato del team dirigenziale e del consiglio di amministrazione è rispettivamente 5.8 anni e 5.8 anni.
Informazioni chiave
Jean-Pierre Sommadossi
Amministratore delegato
US$3.4m
Compenso totale
| Percentuale dello stipendio del CEO | 20.67% |
| Mandato del CEO | 13.8yrs |
| Proprietà del CEO | 8.3% |
| Durata media del management | 5.8yrs |
| Durata media del Consiglio di amministrazione | 5.8yrs |
Aggiornamenti recenti sulla gestione
Recent updates
Hepatitis C Trial And Pricing Risks Will Dominate Outlook Yet Longer Term Potential Remains
Catalysts About Atea Pharmaceuticals Atea Pharmaceuticals focuses on developing oral antiviral therapies for hepatitis C and hepatitis E. What are the underlying business or industry changes driving this perspective?We Think Atea Pharmaceuticals (NASDAQ:AVIR) Needs To Drive Business Growth Carefully
We can readily understand why investors are attracted to unprofitable companies. For example, although...
Hepatitis Antiviral Pipeline Will Create Long Term Upside Potential
Catalysts About Atea Pharmaceuticals Atea Pharmaceuticals focuses on developing oral direct acting antiviral therapies for serious viral infections, including hepatitis C and hepatitis E. What are the underlying business or industry changes driving this perspective?
Hepatitis C And E Antiviral Pipeline Will Reshape Long Term Outlook
Catalysts About Atea Pharmaceuticals Atea Pharmaceuticals is a clinical stage biotechnology company focused on developing oral direct acting antivirals for serious viral infections, including hepatitis C and hepatitis E. What are the underlying business or industry changes driving this perspective?Atea wins FDA Fast Track status for dengue treatment
Atea Pharmaceuticals, Inc. (NASDAQ:AVIR), a biotech focused on developing treatments for viral infections, announced Monday that the FDA granted Fast Track Designation to AT-752, an investigational oral therapy for dengue virus infection. Dengue is the most common mosquito-borne virus in the world, affecting an estimated up to 400M people annually. The FDA offers the Fast Track designation to accelerate the development and review of drugs targeted at serious conditions with unmet medical needs. It allows developers to communicate frequently with the regulator on plans for clinical studies. Developed using AVIR’s purine nucleotide prodrug platform, AT-752 is currently undergoing two proof-of-concept studies for dengue, with data expected at the end of the year. Read more on upcoming milestones for AVIR as outlined by the management in August.Atea Pharmaceuticals Q2 2022 Earnings Preview
Atea Pharmaceuticals (NASDAQ:AVIR) is scheduled to announce Q2 earnings results on Monday, August 8th, after market close. The consensus EPS Estimate is -$0.49 (-2550.0% Y/Y) and the consensus Revenue Estimate is $0M Over the last 3 months, EPS estimates have seen 2 upward revisions and 1 downward.Atea Pharmaceuticals, Inc.'s (NASDAQ:AVIR) Shares Not Telling The Full Story
When close to half the companies in the United States have price-to-earnings ratios (or "P/E's") above 16x, you may...Analysts Just Shaved Their Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) Forecasts Dramatically
Today is shaping up negative for Atea Pharmaceuticals, Inc. ( NASDAQ:AVIR ) shareholders, with the analysts delivering...Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) Analysts Just Slashed Next Year's Estimates
The latest analyst coverage could presage a bad day for Atea Pharmaceuticals, Inc. ( NASDAQ:AVIR ), with the analysts...A Look Into The Ownership Structure of Atea Pharmaceuticals (NASDAQ:AVIR)
Now and then, the volatility of the pharmaceutical sector rears its ugly head, leaving the hordes of investors running for the hills. Leading the decline this week was Atea Pharmaceuticals (NasdaqGS: AVIR) that lost over two-thirds of its value. We will look into this severe decline and reflect on the state of the ownership.A Look Into The Ownership Structure of Atea Pharmaceuticals (NASDAQ:AVIR)
Now and then, the volatility of the pharmaceutical sector rears its ugly head, leaving the hordes of investors running for the hills. Leading the decline this week was Atea Pharmaceuticals (NasdaqGS: AVIR) that lost over two-thirds of its value. We will look into this severe decline and reflect on the state of the ownership.Atea Pharmaceuticals' COVID Antiviral Trial Failure Hands Initiative To Merck's Molnupiravir
Atea Pharmaceuticals posted underwhelming data from a Phase 2 trial of its COVID antiviral therapy AT-527 on Oct. 19, causing its stock price to fall by 66%. The drug failed to meet its endpoint of reduction of the SARS-Cov-2 virus compared to placebo in a subset of patients - around two-thirds of whom were low risk. Atea has a similar mechanism of action to Merck's Molnupiravir, which looks likely to win Emergency Approval for mild-to-moderate COVID-19 patients who are at risk for progressing to severe COVID. If Atea management has used only unvaccinated patients with a serious underlying health issue, as Merck did, the outcome of its MOONSONG trial may have been different. As such, Atea may be able to alter pivotal trial protocols and still make it to market - although yesterday's data means that will not happen for at least another year, by which time, it may be too late.Analisi delle retribuzioni degli amministratori delegati
| Data | Compenso totale | Stipendio | Utili della società |
|---|---|---|---|
| Mar 31 2026 | n/a | n/a | -US$170m |
| Dec 31 2025 | US$3m | US$703k | -US$158m |
| Sep 30 2025 | n/a | n/a | -US$147m |
| Jun 30 2025 | n/a | n/a | -US$136m |
| Mar 31 2025 | n/a | n/a | -US$139m |
| Dec 31 2024 | US$4m | US$703k | -US$168m |
| Sep 30 2024 | n/a | n/a | -US$174m |
| Jun 30 2024 | n/a | n/a | -US$176m |
| Mar 31 2024 | n/a | n/a | -US$164m |
| Dec 31 2023 | US$6m | US$683k | -US$136m |
| Sep 30 2023 | n/a | n/a | -US$131m |
| Jun 30 2023 | n/a | n/a | -US$106m |
| Mar 31 2023 | n/a | n/a | -US$109m |
| Dec 31 2022 | US$6m | US$650k | -US$116m |
| Sep 30 2022 | n/a | n/a | US$36m |
| Jun 30 2022 | n/a | n/a | US$16m |
| Mar 31 2022 | n/a | n/a | US$48m |
| Dec 31 2021 | US$34m | US$650k | US$121m |
| Sep 30 2021 | n/a | n/a | US$25m |
| Jun 30 2021 | n/a | n/a | US$35m |
| Mar 31 2021 | n/a | n/a | US$24m |
| Dec 31 2020 | US$3m | US$437k | -US$11m |
| Sep 30 2020 | n/a | n/a | -US$36m |
| Jun 30 2020 | n/a | n/a | -US$22m |
| Mar 31 2020 | n/a | n/a | -US$16m |
| Dec 31 2019 | US$811k | US$400k | -US$14m |
Compensazione vs Mercato: La retribuzione totale di Jean-Pierre ($USD 3.40M ) è circa la media per le aziende di dimensioni simili nel mercato US ($USD 2.59M ).
Compensazione vs guadagni: La retribuzione di Jean-Pierre è stata coerente con le performance aziendali dell'ultimo anno.
AMMINISTRATORE DELEGATO
Jean-Pierre Sommadossi (69 yo)
Dr. Jean-Pierre Sommadossi, Ph D., is a Founder of Atea Pharmaceuticals, Inc. and has been its Chairman, Director, Chief Executive Officer and President since July 2012 and had been its Treasurer. Dr. Somm...
Gruppo dirigente
| Nome | Posizione | Mandato | Compensazione | Proprietà |
|---|---|---|---|---|
| Founder | 13.8yrs | US$3.40m | 8.29% $ 30.1m | |
| CFO, Executive VP of Legal & Secretary | 12.4yrs | US$1.69m | 1.03% $ 3.7m | |
| Chief Commercial Officer | 7.6yrs | US$1.22m | 0.21% $ 747.9k | |
| Chief Development Officer | 5.8yrs | US$1.77m | 0.16% $ 578.3k | |
| Chief Medical Officer | 5.8yrs | US$1.59m | 0.12% $ 435.3k | |
| Executive VP of Finance & Chief Accounting Officer | 4.3yrs | US$1.52m | 0.099% $ 359.4k | |
| Senior Vice President of Investor Relations & Corporate Communications | 5.3yrs | Nessun dato | Nessun dato | |
| Executive Vice President of Chemistry | no data | Nessun dato | Nessun dato | |
| Executive Vice President of Early Stage Development | no data | Nessun dato | Nessun dato | |
| Executive VP of Clinical Sciences & Project Management | 6.3yrs | Nessun dato | Nessun dato | |
| Executive Vice President of Regulatory Affairs | 5.3yrs | Nessun dato | Nessun dato | |
| Executive Vice President of Preclinical Development | 4.3yrs | Nessun dato | Nessun dato |
Gestione esperta: Il team dirigenziale di AVIR è esperto e expertise (durata media dell'incarico 5.8 anni).
Membri del Consiglio di amministrazione
| Nome | Posizione | Mandato | Compensazione | Proprietà |
|---|---|---|---|---|
| Founder | 13.8yrs | US$3.40m | 8.29% $ 30.1m | |
| Independent Director | 1.3yrs | US$415.33k | 0.057% $ 207.1k | |
| Independent Director | 5.6yrs | US$256.90k | 0.078% $ 284.3k | |
| Independent Director | 11.7yrs | US$249.40k | 0.14% $ 510.8k | |
| Lead Independent Director | 6.7yrs | US$282.90k | 0.63% $ 2.3m | |
| Independent Director | 11.5yrs | US$249.40k | 0.12% $ 431.3k | |
| Independent Director | 5.8yrs | US$251.90k | 0.11% $ 389.8k | |
| Independent Director | 5yrs | US$366.90k | 0.078% $ 284.3k | |
| Independent Director | less than a year | US$407.11k | Nessun dato |
Consiglio di amministrazione esperto: I membri del consiglio di amministrazione di AVIR sono considerati esperti (durata media dell'incarico 5.8 anni).
Analisi aziendale e situazione dei dati finanziari
| Dati | Ultimo aggiornamento (ora UTC) |
|---|---|
| Analisi dell'azienda | 2026/05/27 05:59 |
| Prezzo dell'azione a fine giornata | 2026/05/27 00:00 |
| Utili | 2026/03/31 |
| Utili annuali | 2025/12/31 |
Fonti dei dati
I dati utilizzati nella nostra analisi aziendale provengono da S&P Global Market Intelligence LLC. I seguenti dati sono utilizzati nel nostro modello di analisi per generare questo report. I dati sono normalizzati, il che può comportare un ritardo nella disponibilità della fonte.
| Pacchetto | Dati | Tempistica | Esempio Fonte USA * |
|---|---|---|---|
| Dati finanziari della società | 10 anni |
| |
| Stime di consenso degli analisti | +3 anni |
|
|
| Prezzi di mercato | 30 anni |
| |
| Proprietà | 10 anni |
| |
| Gestione | 10 anni |
| |
| Sviluppi principali | 10 anni |
|
* Esempio per i titoli statunitensi, per i titoli non statunitensi si utilizzano forme e fonti normative equivalenti.
Se non specificato, tutti i dati finanziari si basano su un periodo annuale ma vengono aggiornati trimestralmente. Si tratta dei cosiddetti dati TTM (Trailing Twelve Month) o LTM (Last Twelve Month). Per saperne di più.
Modello di analisi e Snowflake
I dettagli del modello di analisi utilizzato per generare questo report sono disponibili sulla nostra pagina Github; abbiamo anche guide su come utilizzare i nostri report e tutorial su Youtube.
Scoprite il team di livello mondiale che ha progettato e realizzato il modello di analisi Simply Wall St.
Metriche di settore e industriali
Le nostre metriche di settore e di sezione sono calcolate ogni 6 ore da Simply Wall St; i dettagli del nostro processo sono disponibili su Github.
Fonti analitiche
Atea Pharmaceuticals, Inc. è coperta da 4 analisti. 2 di questi analisti ha fornito le stime di fatturato o di utile utilizzate come input per il nostro report. Le stime degli analisti vengono aggiornate nel corso della giornata.
| Analista | Istituzione |
|---|---|
| Eric Joseph | J.P. Morgan |
| Matthew Harrison | Morgan Stanley |
| Maxwell Skor | Morgan Stanley |